Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

NCT01300208 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01300208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01300208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2010
Completion date
March 1, 2013
Enrollment
48 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus